| Aug 5 |
Invitation to the presentation of Calliditas´s interim report January - June 2024
|
| Aug 1 |
Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference
|
| Jul 31 |
Number of shares and votes in Calliditas Therapeutics
|
| Jul 26 |
Calliditas's Kinpegyo gets EU approval, setanaxib study meets endpoint
|
| Jul 26 |
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
|
| Jul 26 |
Calliditas’ Phase IIb trial of PBC treatment meets primary endpoint
|
| Jul 26 |
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
|
| Jul 4 |
Launch of Phase 3 clinical trial with Nefecon in Japan
|
| Jun 18 |
Calliditas provides setanaxib patent update
|
| Jun 17 |
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
|
